secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-05-18T18:15:14+00:00
Accession:  0001193125-26-228639
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx shareholders OK 14.5M-share equity plan; re-elect directors
----------------------------------------------------------------------

- Third Amended and Restated 2023 Incentive Plan approved; up to 14.5M new shares available plus shares from prior plans.
- Emil Kakkis, Shehnaaz Suliman, Daniel G. Welch re-elected as Class I directors to serve until 2029 Annual Meeting.
- Ernst & Young ratified as independent auditor; advisory 'say-on-pay' proposal passed with 70.9M votes for.
- Director compensation limit set at $900k per year ($1.5M for first year or Chair/Lead Director).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/rare-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-228639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer